TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Short Interest Down 45.5% in November

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) was the target of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 31,800 shares, a drop of 45.5% from the October 31st total of 58,400 shares. Based on an average daily volume of 44,200 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.7% of the company’s shares are short sold.

TriSalus Life Sciences Trading Up 7.3 %

NASDAQ:TLSI traded up $0.31 during mid-day trading on Friday, hitting $4.56. The company had a trading volume of 12,179 shares, compared to its average volume of 39,311. The business has a fifty day simple moving average of $4.23 and a 200-day simple moving average of $5.43. TriSalus Life Sciences has a 1 year low of $3.61 and a 1 year high of $10.42. The firm has a market capitalization of $139.05 million, a price-to-earnings ratio of -1.83 and a beta of 0.49.

Insider Transactions at TriSalus Life Sciences

In other news, CEO Mary T. Szela bought 7,520 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were acquired at an average cost of $5.20 per share, with a total value of $39,104.00. Following the transaction, the chief executive officer now owns 377,382 shares of the company’s stock, valued at $1,962,386.40. This represents a 2.03 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have acquired 19,560 shares of company stock worth $95,190 over the last quarter. 32.80% of the stock is currently owned by insiders.

Institutional Trading of TriSalus Life Sciences

Several large investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new stake in shares of TriSalus Life Sciences during the third quarter valued at about $92,000. Geode Capital Management LLC grew its stake in shares of TriSalus Life Sciences by 45.4% during the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after acquiring an additional 62,542 shares in the last quarter. Vestcor Inc acquired a new stake in shares of TriSalus Life Sciences during the third quarter valued at about $108,000. MSD Partners L.P. acquired a new stake in shares of TriSalus Life Sciences during the third quarter valued at about $184,000. Finally, Walleye Capital LLC acquired a new stake in shares of TriSalus Life Sciences during the third quarter valued at about $66,000. 2.58% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

TLSI has been the topic of several research reports. Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Roth Mkm initiated coverage on TriSalus Life Sciences in a research report on Monday, November 11th. They issued a “buy” rating and a $11.00 target price on the stock. Canaccord Genuity Group cut their target price on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Northland Securities started coverage on TriSalus Life Sciences in a research report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price objective on the stock. Finally, Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $12.08.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.